Origen Therapeutics has developed a powerful technology platform in avian genetic engineering. The company’s patent portfolio includes applications on PGCs, modifications of these cells and transgenic chickens derived from them.

In addition, Origen holds the world-wide exclusive license to several gene targeting technologies for use in avian PGCs – essentially a collection of tools for genetic modification of these cells.

In addition Origen has an exclusive license to an issued patent covering eggs containing human antibodies. Several important papers have been published in leading journals such as Nature, Nature Biotechnology, Mechanisms of Development, Molecular Reproduction and Development and Transgenic Research further demonstrating that Origen is the leading company in this field.